ISN-ISE Webinar: Practical Aspects of the Treatment of Diabetic Kidney Disease

Recorded On: 12/16/2021

In patients with CKD the decline in GFR reduces the clearance of insulin and many diabetes medications and raises the risk of hypoglycemia with insulin, sulfonylureas and glinides.GLP1agonists have cardiovascular benefits, andSGLT2 inhibitors significantly decrease kidney and cardiovascular outcomes making them the class of choice for those with CKD. Targets for glycemic control should be individualized taking CKD into consideration, and glycemic control should be monitored with HbA1c, supplemented with SMBG or CGM when hypoglycemia is of concern. Multidisciplinary teamwork with collaboration between GP, endocrinologist and nephrologist is important for success.

Angela Yee Moon Y. Wang

Hong Kong

She is current Deputy Chair of ISN North & East Asia Regional Board, Deputy Chair of ISN Education Working Group. Immediate Past President of International Society of Renal Nutrition and Metabolism (ISRNM), Council member of ISPD, Previous Exe Committee member of KDIGO. Also Committee Member of ISN-ACT, Exe Committee Member of SONG. She has served as a workgroup member of international clinical practice guidelines (CPG) including ISPD Prescribing High Quality Goal-Directed PD Guidelines 2020, ISPD-GREX Practice Recommendations on Physical Activity and Exercise in PD 2021 and KDOQI Nutrition Guidelines 2020 and KDIGO anemia guidelines in CKD 2022. She serves on the editorial board of JASN, Kidney Int, CJASN, NDT (theme Editor), Am J Nephrol, Nephron, etc. She has received ISPD John Maher Award 2006 and NKF Joel D. Kopple Award 2018 and Thomas Addis Award, a lifetime award of the ISRNM in Dec 2022. She has published >200 papers, 15 book chapters, delivered >150 invited lectures in international meetings. She is recognized for her research in cardiovascular, metabolic and nutrition complications in CKD. She works in clinical trials.